AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34154504 — intervention group
Group type: EXPERIMENTAL
Intervention: Medtronic Extended Infusion Set (EIS)
Number of subjects: 0
Study 34154504 — intervention group
Group type: COMPARATOR
Intervention: Standard 2- to 3-day infusion sets
Number of subjects: 0
Study 34154614 — intervention group
Group type: EXPERIMENTAL
Intervention: Envafolimab 150 mg subcutaneously weekly in a 28-day treatment cycle
Number of subjects: 103
Study 34154665 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Eating Index (HEI-2015) dietary patterns
Number of subjects: 393
Study 34154665 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex and age diet pattern models
Number of subjects: 393
Study 34154670 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitation intensity and facilitator resilience as proposed factors in the facilitation process.
Number of subjects: 0
Study 34154670 — intervention group
Group type: EXPERIMENTAL
Intervention: Support for facilitator resilience in healthcare delivery systems.
Number of subjects: 0
Study 34154675 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise prehabilitation
Number of subjects: 38
Study 34154675 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 38
Study 34155079 — intervention group
Group type: EXPERIMENTAL
Intervention: Transition readiness and care experiences
Number of subjects: 0
Study 34155079 — intervention group
Group type: EXPERIMENTAL
Intervention: Transition process
Number of subjects: 0
Study 34155084 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) with a dose range of 30-50 Gy delivered in 1, 3, or 5 daily fractions to all sites of active metastatic disease.
Number of subjects: 205
Study 34155171 — intervention group
Group type: EXPERIMENTAL
Intervention: Capnodynamic method (COEPBF)
Number of subjects: 35
Study 34155171 — intervention group
Group type: COMPARATOR
Intervention: Transpulmonary thermodilution (COTPTD)
Number of subjects: 35
Study 34155211 — intervention group
Group type: EXPERIMENTAL
Intervention: Myo-inositol trispyrophosphate (ITPP)
Number of subjects: 28
Study 34155277 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly diagnosed DM
Number of subjects: 1306
Study 34155277 — intervention group
Group type: EXPERIMENTAL
Intervention: Known DM
Number of subjects: 1306
Study 34155277 — intervention group
Group type: EXPERIMENTAL
Intervention: No DM
Number of subjects: 1306
Study 34155622 — intervention group
Group type: COMPARATOR
Intervention: Oral misoprostol (initial dose ≤ 50 µg)
Number of subjects: 20026
Study 34155622 — intervention group
Group type: COMPARATOR
Intervention: Oral misoprostol
Number of subjects: 20026
Study 34155864 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow mesenchymal stem cells (BMSCs) and growth factors used for activation of ovarian tissue before re-transplantation
Number of subjects: 50
Study 34155864 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow mesenchymal stem cells (BMSCs) and growth factors
Number of subjects: 50
Study 34155907 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual visits after blood pressure control was achieved
Number of subjects: 10
Study 34155907 — intervention group
Group type: COMPARATOR
Intervention: In-person visits prior to achieving BP control
Number of subjects: 10
Study 34155911 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative MRI assessments
Number of subjects: 0
Study 34155911 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle volume measurements
Number of subjects: 0
Study 34156285 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy
Number of subjects: 0
Study 34156285 — intervention group
Group type: COMPARATOR
Intervention: Pembrolizumab alone
Number of subjects: 0
Study 34156303 — intervention group
Group type: EXPERIMENTAL
Intervention: High burden of small airway disease (SAD) ≥15.6%
Number of subjects: 737
Study 34156303 — intervention group
Group type: EXPERIMENTAL
Intervention: High burden of emphysema ≥5%
Number of subjects: 737
Study 34156303 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe exacerbations requiring hospitalization
Number of subjects: 737
Study 34156440 — intervention group
Group type: EXPERIMENTAL
Intervention: PTCy, tacrolimus, and mycophenolate mofetil
Number of subjects: 38
Study 34156524 — intervention group
Group type: EXPERIMENTAL
Intervention: BASILICA procedure
Number of subjects: 15
Study 34156524 — intervention group
Group type: COMPARATOR
Intervention: TAVI without prior successful bioprosthetic leaflet laceration
Number of subjects: 15
Study 34156525 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation (AF) group
Number of subjects: 1685
Study 34156525 — intervention group
Group type: COMPARATOR
Intervention: Sinus rhythm (SR) group
Number of subjects: 1685
Study 34156589 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressed Veterans with PTSD
Number of subjects: 184
Study 34156589 — intervention group
Group type: COMPARATOR
Intervention: Depressed Veterans without PTSD
Number of subjects: 184
Study 34156716 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical examination focusing on auxology and genital development
Number of subjects: 268
Study 34156716 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood (serum, plasma, DNA) and urine samples collected at each visit
Number of subjects: 268
Study 34156716 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental questionnaires and clinical examinations
Number of subjects: 268
Study 34156874 — intervention group
Group type: EXPERIMENTAL
Intervention: huCART19 (humanized CD19 CAR T-cell product)
Number of subjects: 74
Study 34157072 — intervention group
Group type: EXPERIMENTAL
Intervention: Urothelial component of MIBC tumors with secondary variant histology
Number of subjects: 173
Study 34157072 — intervention group
Group type: EXPERIMENTAL
Intervention: Micropapillary cases
Number of subjects: 173
Study 34157072 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarcomatoid tumors
Number of subjects: 173
Study 34157072 — intervention group
Group type: EXPERIMENTAL
Intervention: Small cell cases
Number of subjects: 173
Study 34157072 — intervention group
Group type: EXPERIMENTAL
Intervention: Squamous variant cases
Number of subjects: 173
Study 34157616 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib (60-93 mg/m2) administered orally once daily for 3 weeks on/1 week off; recommended phase 2 dose is 82 mg/m2.
Number of subjects: 41
Study 34157782 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib plus endocrine therapy (125 mg daily; 21 days on and 7 days off)
Number of subjects: 35
Study 34157782 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib plus endocrine therapy (Duffy null variant)
Number of subjects: 35
Study 34157782 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib plus endocrine therapy (wild-type variant)
Number of subjects: 35
Study 34157896 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild impact exposure
Number of subjects: 0
Study 34157896 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 34157997 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial ultrasound (r-US)
Number of subjects: 0
Study 34157997 — intervention group
Group type: COMPARATOR
Intervention: Meander-like ultrasound (m-US)
Number of subjects: 0
Study 34158028 — intervention group
Group type: EXPERIMENTAL
Intervention: mepolizumab 100 mg SC
Number of subjects: 936
Study 34158028 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 936
Study 34158082 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional gender beliefs
Number of subjects: 2792
Study 34158082 — intervention group
Group type: COMPARATOR
Intervention: Progressive gender beliefs
Number of subjects: 2792
Study 34158124 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous PRP injection
Number of subjects: 30
Study 34158124 — intervention group
Group type: COMPARATOR
Intervention: Steroid/anesthetic injection (standard care)
Number of subjects: 30
Study 34158124 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection with normal saline
Number of subjects: 30
Study 34158124 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 30
Study 34158129 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Behavioral Weight Loss plus Weight-Related VR app
Number of subjects: 15
Study 34158129 — intervention group
Group type: COMPARATOR
Intervention: Standard Behavioral Weight Loss plus Non-Weight-Related VR app
Number of subjects: 15
Study 34158129 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall VR program
Number of subjects: 15
Study 34158129 — intervention group
Group type: EXPERIMENTAL
Intervention: VR footage
Number of subjects: 15
Study 34158129 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse effects of VR
Number of subjects: 15
Study 34158129 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference for VR approach
Number of subjects: 15
Study 34158456 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation (PR) with Acute Exacerbation (AE)
Number of subjects: 559
Study 34158456 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation (PR) without Acute Exacerbation (AE)
Number of subjects: 559
Study 34158456 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation (PR) with AE
Number of subjects: 559
Study 34158456 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation (PR) without AE
Number of subjects: 559
Study 34158835 — intervention group
Group type: EXPERIMENTAL
Intervention: Biologicals exposed
Number of subjects: 0
Study 34158835 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunomodulatory exposed
Number of subjects: 0
Study 34158835 — intervention group
Group type: COMPARATOR
Intervention: Non-exposed
Number of subjects: 0
Study 34158835 — intervention group
Group type: EXPERIMENTAL
Intervention: All cohorts
Number of subjects: 0
Study 34159342 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg molnupiravir
Number of subjects: 202
Study 34159342 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg molnupiravir
Number of subjects: 202
Study 34159342 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study 34159343 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous REGEN-COV 1200mg
Number of subjects: 314
Study 34159343 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 314
Study 34159344 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous REGEN-COV (1200 mg)
Number of subjects: 1505
Study 34159344 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1505
Study 34159355 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma choline
Number of subjects: 646
Study 34159355 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma betaine
Number of subjects: 646
Study 34159355 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline and betaine combined
Number of subjects: 646
Study 34159355 — intervention group
Group type: COMPARATOR
Intervention: Control group (free of recurrent cardiovascular events)
Number of subjects: 646
Study 34159373 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting plasma FGF21 concentration
Number of subjects: 109
Study 34159373 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 109
Study 34159555 — intervention group
Group type: EXPERIMENTAL
Intervention: CEUS
Number of subjects: 47
Study 34159555 — intervention group
Group type: EXPERIMENTAL
Intervention: CT
Number of subjects: 47
Study 34159555 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 47
Study 34159555 — intervention group
Group type: EXPERIMENTAL
Intervention: PALP/IOUS/CEIOUS
Number of subjects: 47
Study 34159555 — intervention group
Group type: EXPERIMENTAL
Intervention: IOUS/CEIOUS
Number of subjects: 47
Study 34159555 — intervention group
Group type: COMPARATOR
Intervention: Preoperative imaging
Number of subjects: 47
Study 34159555 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative ultrasound
Number of subjects: 47
Study 34159555 — intervention group
Group type: EXPERIMENTAL
Intervention: CEIOUS
Number of subjects: 47
Study 34159577 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intravenous anti-pseudomonal antibiotic therapy
Number of subjects: 356
Study 34159577 — intervention group
Group type: COMPARATOR
Intervention: Combination intravenous anti-pseudomonal antibiotic therapy
Number of subjects: 356
Study 34160085 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustments to the HPC collection process and procedure
Number of subjects: 2
Study 34160290 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc
Number of subjects: 16
Study 34160290 — intervention group
Group type: EXPERIMENTAL
Intervention: V3-loop genotype analysis
Number of subjects: 16
Study 34160684 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab in combination with modified FOLFOX6
Number of subjects: 0
Study 34160684 — intervention group
Group type: COMPARATOR
Intervention: Modified FOLFOX6 (reduced dose due to safety concerns)
Number of subjects: 0
Study 34160752 — intervention group
Group type: EXPERIMENTAL
Intervention: Talazoparib 0.75 mg once daily
Number of subjects: 9
Study 34160752 — intervention group
Group type: EXPERIMENTAL
Intervention: Talazoparib 1.0 mg once daily
Number of subjects: 9
Study 34160752 — intervention group
Group type: EXPERIMENTAL
Intervention: Talazoparib (both doses)
Number of subjects: 9
Study 34160791 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring group (TMG) with interactive lifestyle educational software and connected devices
Number of subjects: 282
Study 34160791 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) with routine follow-up
Number of subjects: 282
Study 34161579 — intervention group
Group type: EXPERIMENTAL
Intervention: Mosquito bite-induced Plasmodium vivax controlled human malaria infection (PvCHMI)
Number of subjects: 100
Study 34161579 — intervention group
Group type: COMPARATOR
Intervention: Microscopy
Number of subjects: 100
Study 34161579 — intervention group
Group type: COMPARATOR
Intervention: Quantitative PCR
Number of subjects: 100
Study 34161579 — intervention group
Group type: COMPARATOR
Intervention: Quantitative real-time reverse-transcription PCR
Number of subjects: 100
Study 34161597 — intervention group
Group type: EXPERIMENTAL
Intervention: Request for organ donation
Number of subjects: 167
Study 34161597 — intervention group
Group type: EXPERIMENTAL
Intervention: Conversations with ICU physicians
Number of subjects: 167
Study 34161597 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of a documented will
Number of subjects: 167
Study 34161597 — intervention group
Group type: EXPERIMENTAL
Intervention: Opt-out policy for organ donation
Number of subjects: 167
Study 34161597 — intervention group
Group type: EXPERIMENTAL
Intervention: Objection law for organ donation
Number of subjects: 167
Study 34161631 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Number of subjects: 0
Study 34161631 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 34161649 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-guided transurethral ultrasound ablation (TULSA)
Number of subjects: 10
Study 34161665 — intervention group
Group type: EXPERIMENTAL
Intervention: Berotralstat 150 mg once daily
Number of subjects: 227
Study 34161665 — intervention group
Group type: EXPERIMENTAL
Intervention: Berotralstat 110 mg once daily
Number of subjects: 227
Study 34161704 — intervention group
Group type: EXPERIMENTAL
Intervention: Adagrasib
Number of subjects: 38
Study 34161704 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotorasib
Number of subjects: 38
Study 34162178 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A+AVD)
Number of subjects: 186
Study 34162178 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD)
Number of subjects: 186
Study 34162181 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 2510
Study 34162181 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus anticoagulant
Number of subjects: 2510
Study 34162181 — intervention group
Group type: EXPERIMENTAL
Intervention: Periods of thrombocytosis (>600×10^9/L)
Number of subjects: 2510
Study 34162264 — intervention group
Group type: EXPERIMENTAL
Intervention: Fidaxomicin
Number of subjects: 294
Study 34162264 — intervention group
Group type: COMPARATOR
Intervention: Other CDI therapies
Number of subjects: 294
Study 34162404 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard intensive chemotherapy
Number of subjects: 563
Study 34162435 — intervention group
Group type: EXPERIMENTAL
Intervention: CAP-RA questionnaire
Number of subjects: 250
Study 34162435 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly pain and fatigue data collection via text messages
Number of subjects: 250
Study 34162435 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative sensory testing modalities
Number of subjects: 250
Study 34162435 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood markers, swollen joints, and ultrasound scans
Number of subjects: 250
Study 34162435 — intervention group
Group type: EXPERIMENTAL
Intervention: Test-retest reliability of CAP-RA questionnaire
Number of subjects: 250
Study 34162435 — intervention group
Group type: EXPERIMENTAL
Intervention: CAP-RA psychometric properties and predictive validity
Number of subjects: 250
Study 34162668 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34162982 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal MMC repair (fetoscopic or open-hysterotomy)
Number of subjects: 63
Study 34163157 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab 100 mg SC
Number of subjects: 1136
Study 34163157 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of Mepolizumab (100 mg and 300 mg SC)
Number of subjects: 1136
Study 34163157 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1136
Study 34163180 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab (75 mg intravenously or 100 mg subcutaneously)
Number of subjects: 576
Study 34163180 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 576
Study 34164554 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 30
Study 34164554 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 34164709 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors (ICI)
Number of subjects: 123
Study 34164709 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors (ICI) with corticosteroid treatment
Number of subjects: 123
Study 34164709 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors (ICI) with occurrence of irAE
Number of subjects: 123
Study 34164713 — intervention group
Group type: EXPERIMENTAL
Intervention: Tivantinib (120-360 mg orally twice daily) + Bevacizumab (10 mg/kg intravenously every 2 weeks)
Number of subjects: 11
Study 34164713 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab (10 mg/kg intravenously every 2 weeks)
Number of subjects: 11
Study 34164713 — intervention group
Group type: EXPERIMENTAL
Intervention: Tivantinib + Bevacizumab
Number of subjects: 11
Study 34164711 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine (LC) 5 mM
Number of subjects: 0
Study 34164711 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetyl-L-carnitine (ALC) 5 mM
Number of subjects: 0
Study 34164711 — intervention group
Group type: EXPERIMENTAL
Intervention: Propionyl-L-carnitine (PLC) 5 mM
Number of subjects: 0
Study 34164803 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced dietary salt intake (mean -73.51 mmol/day, equivalent to 4.2 g or 1690 mg sodium/day)
Number of subjects: 1197
Study 34164803 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced dietary salt intake
Number of subjects: 1197
Study 34164952 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (RTX) 375 mg/m² intravenous infusions during the initial 6-month remission-induction phase.
Number of subjects: 25
Study 34164952 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (RTX) 375 mg/m² intravenous infusions.
Number of subjects: 25
Study 34165180 — intervention group
Group type: EXPERIMENTAL
Intervention: Takotsubo syndrome (TTS) patients
Number of subjects: 2848
Study 34165180 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous coronary artery dissection (SCAD) patients
Number of subjects: 2848
Study 34165201 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 or 10 mg twice daily (b.d.)
Number of subjects: 0
Study 34165201 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg b.d.
Number of subjects: 0
Study 34165201 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34165661 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid-flow expulsion maneuver (RFEM)
Number of subjects: 241
Study 34165661 — intervention group
Group type: COMPARATOR
Intervention: Subglottic secretion drainage (SSD)
Number of subjects: 241
Study 34165694 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab (12 mg/day; 5 days at baseline; 3 days at 12 months)
Number of subjects: 511
Study 34166063 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective Serotonin Reuptake Inhibitors (SSRIs)
Number of subjects: 0
Study 34166150 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 83182
Study 34166150 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 83182
Study 34166393 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyronaridine-artesunate (Pyramax)
Number of subjects: 4
Study 34166393 — intervention group
Group type: COMPARATOR
Intervention: Methylene blue
Number of subjects: 4
Study 34166393 — intervention group
Group type: COMPARATOR
Intervention: Pyronaridine
Number of subjects: 4
Study 34166508 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump CABG (OPCAB)
Number of subjects: 1016
Study 34166508 — intervention group
Group type: EXPERIMENTAL
Intervention: All REQUEST patients
Number of subjects: 1016
Study 34166588 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Mood Stabilizers
Number of subjects: 0
Study 34166588 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34166589 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive Mood Stabilizers
Number of subjects: 0
Study 34166589 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0